Cargando…
Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously
BACKGROUND: While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. METHODS: Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091745/ https://www.ncbi.nlm.nih.gov/pubmed/35572450 http://dx.doi.org/10.1016/j.jseint.2022.01.008 |
_version_ | 1784704995985195008 |
---|---|
author | Rogers, Thomas H. Labott, Joshua R. Austin, Daniel C. Barlow, Jonathan D. Morrey, Mark E. Sanchez-Sotelo, Joaquin Sperling, John W. |
author_facet | Rogers, Thomas H. Labott, Joshua R. Austin, Daniel C. Barlow, Jonathan D. Morrey, Mark E. Sanchez-Sotelo, Joaquin Sperling, John W. |
author_sort | Rogers, Thomas H. |
collection | PubMed |
description | BACKGROUND: While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. METHODS: Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty while prescribed clopidogrel. There were 33 (57%) reverse shoulder arthroplasties and 25 (43%) TSAs performed. Patients were separated into two groups based upon their use of clopidogrel in the preoperative period. Twenty patients (35%; group 1) continued clopidogrel through surgery, and 38 patients (65%; group 2) did not. The mean age was 74 years, and the mean follow-up was 42 months. RESULTS: Both groups demonstrated substantial improvements in pain and motion: visual analog scale pain improved by 7 points (P < .001), elevation by 71° (P < .001), external rotation by 29° (P < .001), and internal rotation by 1.7 points (P < .001), with no significant difference between groups. At the final follow-up, the mean American Shoulder and Elbow Surgeons score was 77 in group 1 and 86 in group 2 (P = .067, minimum clinically important difference = 9). Estimated blood loss was 176 mL in group 1 and 127 in group 2 (P = .02). There was one transfusion in group 1 (5%) and 0 in group 2 (P = .16). The 90-day complication rates were 3/20 (15%) in group 1 and 0/37 in group 2 (hazard ratio = 13, P = .14). There was no statistically significant difference between groups for 30-day adverse cardiac events (2.6% and 0%, respectively, P = .46). CONCLUSION: For the patients who continued clopidogrel preoperatively, estimated blood loss was significantly higher and trended toward a lower American Shoulder and Elbow Surgeons score (with differences meeting the minimum clinically important difference) and a higher 90-day complication rate. Perioperative continuation of clopidogrel in shoulder arthroplasty should be approached cautiously. |
format | Online Article Text |
id | pubmed-9091745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90917452022-05-12 Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously Rogers, Thomas H. Labott, Joshua R. Austin, Daniel C. Barlow, Jonathan D. Morrey, Mark E. Sanchez-Sotelo, Joaquin Sperling, John W. JSES Int Shoulder BACKGROUND: While the effect of clopidogrel on outcomes in elective hip and knee arthroplasty has been well described, there is a paucity of data regarding elective shoulder arthroplasty. METHODS: Fifty-eight patients were identified who underwent primary anatomic total shoulder arthroplasty (TSA) or reverse shoulder arthroplasty while prescribed clopidogrel. There were 33 (57%) reverse shoulder arthroplasties and 25 (43%) TSAs performed. Patients were separated into two groups based upon their use of clopidogrel in the preoperative period. Twenty patients (35%; group 1) continued clopidogrel through surgery, and 38 patients (65%; group 2) did not. The mean age was 74 years, and the mean follow-up was 42 months. RESULTS: Both groups demonstrated substantial improvements in pain and motion: visual analog scale pain improved by 7 points (P < .001), elevation by 71° (P < .001), external rotation by 29° (P < .001), and internal rotation by 1.7 points (P < .001), with no significant difference between groups. At the final follow-up, the mean American Shoulder and Elbow Surgeons score was 77 in group 1 and 86 in group 2 (P = .067, minimum clinically important difference = 9). Estimated blood loss was 176 mL in group 1 and 127 in group 2 (P = .02). There was one transfusion in group 1 (5%) and 0 in group 2 (P = .16). The 90-day complication rates were 3/20 (15%) in group 1 and 0/37 in group 2 (hazard ratio = 13, P = .14). There was no statistically significant difference between groups for 30-day adverse cardiac events (2.6% and 0%, respectively, P = .46). CONCLUSION: For the patients who continued clopidogrel preoperatively, estimated blood loss was significantly higher and trended toward a lower American Shoulder and Elbow Surgeons score (with differences meeting the minimum clinically important difference) and a higher 90-day complication rate. Perioperative continuation of clopidogrel in shoulder arthroplasty should be approached cautiously. Elsevier 2022-02-13 /pmc/articles/PMC9091745/ /pubmed/35572450 http://dx.doi.org/10.1016/j.jseint.2022.01.008 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Shoulder Rogers, Thomas H. Labott, Joshua R. Austin, Daniel C. Barlow, Jonathan D. Morrey, Mark E. Sanchez-Sotelo, Joaquin Sperling, John W. Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously |
title | Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously |
title_full | Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously |
title_fullStr | Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously |
title_full_unstemmed | Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously |
title_short | Perioperative clopidogrel (Plavix) continuation in shoulder arthroplasty: approach cautiously |
title_sort | perioperative clopidogrel (plavix) continuation in shoulder arthroplasty: approach cautiously |
topic | Shoulder |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091745/ https://www.ncbi.nlm.nih.gov/pubmed/35572450 http://dx.doi.org/10.1016/j.jseint.2022.01.008 |
work_keys_str_mv | AT rogersthomash perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously AT labottjoshuar perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously AT austindanielc perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously AT barlowjonathand perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously AT morreymarke perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously AT sanchezsotelojoaquin perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously AT sperlingjohnw perioperativeclopidogrelplavixcontinuationinshoulderarthroplastyapproachcautiously |